Bristol-Myers Squibb (BMY, Pharmaceuticals) Stock Valuation & Fair Value Mixed on our tests
Bristol-Myers Squibb (BMY, Pharmaceuticals) trades at a blended P/E of 9.0, about 48% below its historical normal valuation, with a forward growth estimate of -7.0%. Analysts' one-year estimates have been hit 45% of the time. Priced at its historical normal P/E of 17.4 on the same blended earnings, the 2026-10-02 close of $61.15 corresponds to about $117 a share. This is a valuation reference, not a price target.
- Price $59.58 at the 2026-10-08 close, 3.2% below the 20-day average ($61.56) and 6.4% below the 50-day ($63.64).
- RSI (14) at 37.7.
- 52-week range $40.79 to $67.39: the price is 11.6% below the high and 46.1% above the low.
The Street vs SeerForecast
Wall Street's mean price target for BMY is $66.71 across 24 analysts, 12.0% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Negative growth forecast
Verdict history
tickerseer's rating has been mixed on our tests since 2026-06-10.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 36 weeks
Frequently asked questions
Is Bristol-Myers Squibb stock overvalued?
At a blended P/E of 9.0 versus its historical normal P/E of 17.4, Bristol-Myers Squibb trades about 48% below its typical valuation. tickerseer currently rates it mixed on our tests.
What is Bristol-Myers Squibb's fair value and PEG?
Bristol-Myers Squibb trades at a blended P/E of 9.0 against a historical normal P/E of 17.4, a forward growth estimate of -7.0%. Priced at its historical normal P/E of 17.4 on the same blended earnings, the 2026-10-02 close of $61.15 corresponds to about $117 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Bristol-Myers Squibb changed?
tickerseer's rating has been mixed on our tests since 2026-06-10.
What is the analyst price target for Bristol-Myers Squibb?
The mean Wall Street price target for Bristol-Myers Squibb is $66.71 across 24 analysts, 12.0% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.